Immunotherapy of murine leukemia VI. Development of immunologic memory in mice protected against Friend leukemia virus-induced disease by passive serum therapy.
The resistance of DBA/2 mice to infection with a leukemogenic dose of Friend leukemia virus (FLV) as a result of the passive administration of chimpanzee anti-FLV serum is maintained for at least six months after infection and is accompanied by the continued synthesis of mouse anti-viral antibodies analogous to that previously found to be associated with short-term protection (approx. 30 days). Furthermore, the induction of immunologic memory in serum-protected mice is demonstrated by their long-term resistance to rechallenge with FLV of FLV-infected leukemic spleen cells, although cells of an established transplantable syngeneic FLV-erythroleukemia (FLC-745) are not rejected. In the course of these studies, a serum prophylaxis effect was defined in DBA/2 mice treated with the chimpanzee anti-FLV serum before, rather than after FLV infection. The prophylaxis effect is highly dependent on the time period between the last serum inoculation and virus challenge. The results indicate that the long-term resistance of therapeutically protected mice to subsequent virus or leukemic cell challenge is not due to the short-term prophylactic effect of serum treatment alone.
D000818:Animals; D002460:Cell Line; D005622:Friend murine leukemia virus; D007116:Immunization, Passive; D007156:Immunologic Memory; D004915:Leukemia, Erythroblastic, Acute / Q000517:prevention & control / Q000628:therapy; D007942:Leukemia, Experimental / Q000517:prevention & control / Q000628:therapy*; D051379:Mice; D008811:Mice, Inbred DBA; D009368:Neoplasm Transplantation; D013154:Spleen / Q000276:immunology